Navigation Links
Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
Date:7/17/2008

BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) today announced that it received a notice from the NASDAQ Listing Qualifications Hearings Panel on July 16, 2008 indicating that the NASDAQ Panel has determined to grant Sonus' request to continue the listing of its securities on The NASDAQ Global Market. The Company's continued listing on NASDAQ is subject to its compliance with certain conditions by August 29, 2008, including the implementation of a reverse stock split, the completion of its planned merger with OncoGenex Technologies Inc., and approval from NASDAQ of the combined entity's application for initial listing on The NASDAQ Capital Market upon completion of the merger.

"This extension provides the time to implement the resolutions we have proposed to shareholders, including the issuance of shares to consummate the merger with OncoGenex and the reverse stock split, which together we believe will better position the new company to maintain listing on The NASDAQ Capital Market. All of which we believe are in the best interests of shareholders," said Michael A. Martino, President and CEO.

The NASDAQ Panel's exception is subject to certain conditions, such as requiring Sonus to inform the NASDAQ Panel of any significant events that may impact Sonus' ability to maintain compliance with the NASDAQ listing requirements or the exception deadline, and is subject to review by the NASDAQ Listing and Hearing Review Council for a period of 45 days from the date of the NASDAQ Panel's determination letter. Sonus expects to be able to comply with the NASDAQ Panel's conditions for continued listing on The NASDAQ Global Market; however, there can be no assurance that Sonus will be able to do so. Failure to comply with the conditions for listing could result in the delisting of Sonus' shares from NASDAQ.

About Sonus Pharmaceuticals, Inc.

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit http://www.sonuspharma.com.

About OncoGenex Technologies Inc.

OncoGenex Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.OncoGenex.ca.

Definitive Agreement to Merge

On May 28, 2008, Sonus and OncoGenex jointly announced the signing of a definitive agreement to merge the two companies. The proposed transaction is expected to be completed prior to August 29, 2008, subject to the satisfaction of certain conditions, including the approval of Sonus' and OncoGenex' shareholders and, in the case of OncoGenex, court approval under the arrangement provisions of the Canada Business Corporations Act.

Forward-Looking Statements

Certain statements made in this press release are forward-looking such as those, among others, relating to the listing of the Sonus' stock on The NASDAQ Capital Market and the timing of the merger with OncoGenex. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the ability of Sonus to obtain shareholder approval of the issuance of shares in connection with the merger with OncoGenex or the reverse stock split, volatility in the value of Sonus' common stock, the potential inability of Sonus and OncoGenex to complete the merger, and the ability of Sonus to meet the initial listing standards of The NASDAQ Capital Market. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, its Quarterly Report on Form 10-Q for the first quarter of 2008, and its definitive proxy statement filed July 3, 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE Sonus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
3. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. ViroPharma To Acquire Lev Pharmaceuticals
6. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
7. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
8. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
11. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):